A cash-rich orphan-drug winner faces a patent cliff in Cushing’s just as relacorilant’s ovarian-cancer PDUFA becomes the make-or-break pivot to an oncology future.
Overview
Corcept Therapeutics (CORT) is a commercial-stage biopharma built around cortisol modulation, historically dominated by Korlym (mifepristone), which has generated a highly profitable niche endocrine franchise since its 2012 approval in Cushing’s-related hyperglycemia. In FY2025 the company produced $761.4M revenue (+~13% YoY) and $99.7M net income, supported by exceptional gross margins (~98%+), a specialized prescriber base, and a direct-to-specialty-pharmacy distribution model—though a vendor transition constrained revenue realization despite a record 37% increase in tablet volume. Corcept enters 2026 with a major strategic inflection: strong Phase 3 oncology data for relacorilant in platinum-resistant ovarian cancer (ROSELLA met overall survival; PDUFA July 11, 2026) contrasts sharply with two existential headwinds—an FDA Complete Response Letter for relacorilant in Cushing’s (implying new clinical data and delay) and a Federal Circuit decision undermining Korlym’s patent-based protection against Teva’s generic. The investment case therefore centers on whether Corcept can pivot from a threatened single-product endocrine company to a diversified oncology-led growth story, using its debt-free balance sheet (~$532M cash/investments) and disciplined repurchases (~$246M in 2025) to bridge regulatory, legal, and commercialization risk.